p53 Gene therapy for lung cancer.
The gene transfer of the tumor suppressor p53 gene has been shown to induce tumor regression in preclinical models. Recent phase I and II studies have been completed in lung cancer with adenoviral-mediated transfer of wild-type p53 (Ad-p53) either alone or in combination with chemotherapy or radiotherapy. These studies have demonstrated acceptable toxicity and evidence of tumor regression with intratumoral delivery of Ad-p53. The predominant clinical effect appears to be locoregional in the area of intratumoral delivery. Further phase III studies are needed to determine if Ad-p53 will play a therapeutic role as a novel agent to treat non-small-cell lung cancer.
Swisher
Stephen G
SG
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 445, Houston 77030, USA. sswisher@mdanderson.org
Roth
Jack A
JA
D000256:Adenoviridae; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018014:Gene Transfer Techniques; D016158:Genes, p53; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000628:therapy*